Skip to main content
. Author manuscript; available in PMC: 2019 Oct 2.
Published in final edited form as: Structure. 2018 Aug 23;26(10):1360–1372.e5. doi: 10.1016/j.str.2018.07.004

Figure 2: In vitro resistance profile of NS3/4A protease inhibitors.

Figure 2:

a) Enzyme inhibition constants (against protease domain) and b) replicon-based half maximal effective concentrations for WT HCV NS3/4A and drug-resistant variants Y56H, D168A and Y56H/D168A. All inhibitors lost activity against the Y56H/D168A protease variant. * Indicates EC50 value greater than 500. See also Tables S1 and S2.